How It Works
Bottom Line: Pau D'arco has shown antibacterial and anticancer activities in laboratory studies but these effects have not been shown in humans.
Pau D'arco, a tree native to South America, has been used in traditional medicine for a wide range of ailments. In laboratory studies, compounds extracted from Pau d'arco showed antibacterial, antifungal, and anticancer activites. However, the safety and effectiveness of these compounds have not been tested in humans.
Purported Uses
To treat cancer
A small study done on 21 cancer patients did not show any benefits of Pau D'arco.
To treat infections
Laboratory studies showed that Pau D'arco has antibacterial and antifungal activities. It has not been tested in humans.
Research Evidence
Cancer treatment
This was a small study of 21 patients with non-leukemic tumors or chronic myelocytic leukemia. Patients were given 250 to 3750 mg of Pau d'arco every day for up to 21 days. Researches reported that Pau d'arco had no effect on the patients at the end of the study period.
Warnings
Some compounds found in Pau D'arco may have toxic effects.
This product is regulated by the FDA as a dietary supplement. Unlike approved drugs, supplements are not required to be manufactured under specific standardized conditions. This product may not contain the labeled amount or may be contaminated. In addition, it may not have been tested for safety or effectiveness.
Do Not Take If
You are taking warfarin or other blood thinners (Pau d'arco may increase the risk of bruising and bleeding).
Side Effects
Nausea
Vomiting
Dizziness
Anemia
Increased risk of bleeding
Discoloration of urine
Scientific Name
Tabebuia impetiginosa, Tabebuia avellanedae, Tabebuia heptaphylla
Common Name
Ipe-Roxo, lapacho, purple lapacho, trumpet bush and taheebo
Clinical Summary
Pau D'arco is a tree native to South America. Preparations derived from the bark have been traditionally used to treat bacterial, fungal, viral infections, and cancer. In vitro studies of compounds isolated from Pau D'arco demonstrated antibacterial (3) (4) (5) (6), antifungal (7), antipsoriatic (8), immunomodulatory (9) (10), anticancer (11) (12) (13) (14), and antimetastatic (14) activities. Quinones, the main constituents, have been shown to be the active principle (11) (12) (13) (14). In a small single-arm study, Lapachol, a naphthoquinone isolated from the tree bark, did not show any effects on patients with non-leukemic tumors or CML (chronic myelocytic leukemia) (15). Reported adverse events from use of Pau D'arco include nausea, vomiting, dizziness and anemia (16). This herb may also enhance the activity of anticoagulants (17).
Purported uses
Cancer treatment
Antibacterial
Antifungal
Constituents
Quinone compounds: Lapachol, beta-lapachone, xyloidone (naphthoquinones) and tabebuin (anthroquinone)
Flavonoids: Quercetin
Glycosides: Iridoid, lignan, isocoumarin, phenylthanoid, phenolic
Cyclopentene dialdehydes
(1) (2) (3)
Mechanism of Action
The anticancer activity of beta-lapachone, a quinone compound isolated from Pau D'arco, may be due to down regulation of COX-2 (cyclooxygenase) and telomerase activities
(11). Beta-lapachone also induces apoptosis in cancer cells via mitochondrial-signaling
(12) or by activation of caspase
(3) and
(9) enzymes
(18). The anti-metastatic activity of beta-lapachone was shown to be due to decreasing the invasive ability of cancer cells by inducing Egr-1 that is known to suppress metatstasis
(14).
Warnings
Some constituents may have toxic effects. The effectiveness of Pau d'arco for the treatment of cancer in humans remains unproven.
Adverse Reactions
Reported: Nausea, vomiting, dizziness, anemia, bleeding, and discoloration of urine (16).
Herb-Drug Interactions
Anticoagulants: Pau d'arco may potentiate effects
(17).
Literature Summary and Critique
References
1. Warashina T, Nagatani Y, Noro T.
Further constituents from the bark of Tabebuia impetiginosa. Phytochemistry. 2005;66(5):589-597.
2. Koyama J, Morita I, Tagahara K, Hirai K.
Cyclopentene dialdehydes from Tabebuia impetiginosa. Phytochemistry. 2000;53(8):869-872.
3. Park BS, Lee HK, Lee SE, et al.
Antibacterial activity of Tabebuia impetiginosa Martius ex DC (Taheebo) against Helicobacter pylori. J Ethnopharmacol. 2006;105(1-2):255-262.
4. Anesini C, Perez C.
Screening of plants used in Argentine folk medicine for antimicrobial activity. J Ethnopharmacol. 1993;39(2):119-128.
5. Park BS, Kim JR, Lee SE, et al.
Selective growth-inhibiting effects of compounds identified in Tabebuia impetiginosa inner bark on human intestinal bacteria.J Agric Food Chem. 2005;53(4):1152-1157.
6. Pereira EM, Machado Tde B, Leal IC, et al. Tabebuia
avellanedae naphthoquinones: activity against methicillin-resistant staphylococcal strains, cytotoxic activity and in vivo dermal irritability analysis. Ann Clin Microbiol Antimicrob. 2006;5:5.
7. Portillo A, Vila R, Freixa B, et al.
Antifungal activity of Paraguayan plants used in traditional medicine. J Ethnopharmacol. 2001;76(1):93-98.
8. Muller K, Sellmer A, Wiegrebe W.
Potential antipsoriatic agents: lapacho compounds as potent inhibitors of HaCaT cell growth. J Nat Prod. 1999;62(8):1134-1136.
9. Bohler T, Nolting J, Gurragchaa P, et al.
Tabebuia avellanedae extracts inhibit IL-2-independent T-lymphocyte activation and proliferation.Transpl Immunol. 2008;18(4):319-323.
10. Son DJ, Lim Y, Park YH, et al.
Inhibitory effects of Tabebuia impetiginosa inner bark extract on platelet aggregation and vascular smooth muscle cell proliferation through suppressions of arachidonic acid liberation and ERK1/2 MAPK activation. J Ethnopharmacol. 2006;108(1):148-151.
11. Lee JH, Cheong J, Park YM, Choi YH.
Down-regulation of cyclooxygenase-2 and telomerase activity by beta-lapachone in human prostate carcinoma cells. Pharmacol Res. 2005;51(6):553-560.
12. Lee JI, Choi DY, Chung HS, et al.
beta-lapachone induces growth inhibition and apoptosis in bladder cancer cells by modulation of Bcl-2 family and activation of caspases. Exp Oncol. 2006;28(1):30-35.
13. Kung HN, Chien CL, Chau GY, et al.
Involvement of NO/cGMP signaling in the apoptotic and anti-angiogenic effects of beta-lapachone on endothelial cells in vitro. J Cell Physiol. 2007;211(2):522-532.
14. Kim SO, Kwon JI, Jeong YK, et al.
Induction of Egr-1 is associated with anti-metastatic and anti-invasive ability of beta-lapachone in human hepatocarcinoma cells. Biosci Biotechnol Biochem. 2007;71(9):2169-2176.
15. Block JB, Serpick AA, Miller W, Wiernik PH.
Early clinical studies with lapachol (NSC-11905). Cancer Chemother Rep 2. 1974;4(4):27-28.
16. Foster S. Tyler's Honest Herbal: A Sensible Guide to the Use of Herbs and Related Remedies. New York: Haworth Herbal Press; 1999.
17. Brinker F. Herb Contraindications and Drug Interactions. 2nd ed. Sandy (OR): Eclectic Med Publications; 1998.
18. Woo HJ, Park KY, Rhu CH, et al.
Beta-lapachone, a quinone isolated from Tabebuia avellanedae, induces apoptosis in HepG2 hepatoma cell line through induction of Bax and activation of caspase. J Med Food. 2006;9(2):161-168.
